Nyxoah SA (NYXH)
| Market Cap | 145.10M -36.3% |
| Revenue (ttm) | 11.76M +121.6% |
| Net Income | -105.77M |
| EPS | -2.78 |
| Shares Out | 43.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,882 |
| Open | 3.300 |
| Previous Close | 3.260 |
| Day's Range | 3.215 - 3.330 |
| 52-Week Range | 2.760 - 8.640 |
| Beta | 0.88 |
| Analysts | Strong Buy |
| Price Target | 9.33 (+182.71%) |
| Earnings Date | May 12, 2026 |
About NYXH
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Financial Performance
In 2025, Nyxoah's revenue was 10.02 million, an increase of 121.63% compared to the previous year's 4.52 million. Losses were -90.09 million, 52.1% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NYXH stock is "Strong Buy." The 12-month stock price target is $9.33, which is an increase of 182.71% from the latest price.
News
Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026
Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026 Mont-Saint-Guibert, Belgium – April 28, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or t...
Nyxoah price target lowered to $8 from $10 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Nyxoah (NYXH) to $8 from $10 and keeps a Buy rating on the shares. The firm’s checks suggest the Q1
Nyxoah price target lowered to $4.62 from $5.87 at Baird
Baird analyst David Rescott lowered the firm’s price target on Nyxoah (NYXH) to $4.62 from $5.87 and keeps a Neutral rating on the shares. The firm updatedits mdel as its
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), March 20, 2026 , 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 20...
Nyxoah price target lowered to $10 from $11 at Stifel
Stifel lowered the firm’s price target on Nyxoah (NYXH) to $10 from $11 and keeps a Buy rating on the shares. The firm, which updated its model for “some moving
Nyxoah Earnings Call Transcript: Q4 2025
2025 saw transformative growth with FDA approval and U.S. launch, driving 122% revenue growth and strong Q4 results. U.S. net revenue is expected to grow 25% sequentially in early 2026, with expanding sales coverage and improving gross margins.
Nyxoah reports Q4 EPS (EUR 0.59) vs. (EUR 0.46) last year
Reports Q4 revenue EUR 5.64M vs. EUR 1.26M last year. “The fourth quarter marked our first full quarter of U.S. commercialization, and we are very pleased with the strong momentum
Nyxoah sees Q1 revenue up 25% vs. Q4
The company said, “We expect U.S. net revenue for the first quarter of 2026 to grow by approximately 25% over the fourth quarter of 2025 and expect net revenue for
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of Sales Foundation Establishe...
Nyxoah Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Genio's differentiated bilateral neuromodulation technology for sleep apnea is gaining traction in the U.S. and internationally, with strong clinical evidence, robust reimbursement, and a focused commercialization strategy. Recent CMS updates ensure reimbursement parity, and the company targets break-even at €150 million revenue with high gross margins.
Publication relating to transparency notification
REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), March 13, 2026 , 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Law of May 2, 20...
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Nyxoah to Participate in the Oppenheimer 36 th Annual Healthcare MedTech & Services Conference
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)...
Information on the total number of voting rights and shares
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 25, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law...
Nyxoah signs MoU with Sheikh Shakhbout Medical City
Nyxoah (NYXH) announced the signature of a memorandum of understanding, or MoU, with Sheikh Shakhbout Medical City, or SSMC, a hospital in the United Arab Emirates for serious and complex
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
Nyxoah price target lowered to $11 from $12 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Nyxoah (NYXH) to $11 from $12 and keeps a Buy rating on the shares as part of the firm’s Animal
Nyxoah to invest in manufacturing facility in Belgium
Nyxoah (NYXH) announced an investment in Belgium to further scale its manufacturing capacity. In addition to its existing contract manufacturing operations in the United States, the company will expan...
Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth
Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Mont-Saint-Guibert, Belgium – January 21, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext B...
Nyxoah Transcript: 44th Annual J.P. Morgan Healthcare Conference
A differentiated neurostimulation solution for sleep apnea is rapidly gaining traction in the U.S. following FDA approval, with strong clinical evidence, high patient satisfaction, and robust reimbursement. Strategic expansion and innovation are set to drive further growth.
Nyxoah sees Q1 net revenue up 25% over Q1
International revenue is expected to follow a typical seasonal pattern.
Nyxoah reports preliminary Q4 gross revenue EUR 6.3M
Reports preliminary FY25 gross revenue EUR 11M. “Our first full quarter of U.S. commercialization post-FDA approval resulted in strong momentum,” commented Olivier Taelman, Nyxoah’s (NYXH) CEO. “Our f...
Publication relating to transparency notification
REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), January 12, 2026 , 7:00 am CET / 1:00 am ET – In accordance with article 14 of the Law of May 2, 2...
Nyxoah Announces Issuance of First Tranche of Convertible Bonds
Nyxoah Announces Issuance of First Tranche of Convertible Bonds Mont-Saint-Guibert, Belgium – December 19, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “...
Nyxoah announces commercial launch of Genio system in the Netherlands
Nyxoah (NYXH) announced the commercial launch of its Genio system in the Netherlands, marked by the first successful Genio implants performed at OLVG West in Amsterdam and Zuyderland Hospital in